$VIVO (Meridian Bioscience, Inc.)

$VIVO {{ '2016-09-26T18:20:53+0000' | timeago}} • Announcement

Life sciences company $VIVO amended its license agreement with Eiken Chemical Co., Ltd. for its Loop-mediated Isothermal Amplification (LAMP) technology for the areas of animal, food and water testing. The new agreement allows $VIVO to use the LAMP technology to detect infectious agents causing disease in animals or contaminants in food or water.

$UNH {{ '2017-10-18T15:11:12+0000' | timeago}} • Webcast

$UNH's health services business Optum seems to be on a roll. Optum's third quarter revenues eclipsed 8.4% to $23Bil, which is nearly half of $UNH’s total revenues. All business segments of Optum have generated double-digit earnings growth in 3Q. OptumHealth now directly reaches 90MM US consumers, which is an increase of 9MM vs. last year.

$UNH {{ '2017-10-17T19:30:35+0000' | timeago}} • Announcement

$UNH is the first firm amongst its peers to report earnings every quarter. For the first time in its history, it is on track to cross revenues of $200Bil in 2017. 3Q revenues jumped 9% to $50.3Bil. $UNH's withdrawal from ACA individual insurance markets, along with a health insurance tax deferral, reduced revenues by $1.6Bil and growth rate by 4%.

$JNJ {{ '2017-10-17T19:25:16+0000' | timeago}} • Webcast

$JNJ said, "The key factor to Remicade being successful is physicians and patients have a high confidence in it based on experience that they don't want to switch to an alternative." The company was responding to a question on rival $PFE's lawsuit against it for allegedly using unfair means to protect Remicade from competitors.

$JNJ {{ '2017-10-17T19:18:23+0000' | timeago}} • Webcast

$JNJ said sale of its blockbuster drug Remicade, used in the treatment of rheumatoid-arthritis declined 7.6% to $1.6Bil in 3Q17, hurt by competition from cheaper alternatives called biosimilars. The pharma giant said it has reduced Remicade's price, in view of tight competition in the market.

$JNJ {{ '2017-10-17T18:41:27+0000' | timeago}} • Webcast

Speaking on the effect of Hurricane Maria that hit Puerto Rico last month, $JNJ said all six of its plants on the island are making and shipping drugs using energy from generators. Though the company said intermittent shortage of drugs cannot be ruled out, it added that it does not see any material impact of the hurricane on future results.

$UNH {{ '2017-10-17T17:16:02+0000' | timeago}} • Announcement

$UNH reported 26% jump in its profits aided by strong growth in its Optum business. This is the first quarter the health insurer is reporting results under the helm of new CEO Dave Wichmann, who replaced Steve Hemsley in September. The company also raised its outlook for 2017. It now expects GAAP EPS to touch $9.45 and adjusted EPS to reach $10.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$JNJ {{ '2017-10-17T13:40:49+0000' | timeago}} • Webcast

Only months after promising investors a slew of new blockbuster drugs, $JNJ said it has decided to discontinue clinical trials for two of its drugs. Sirukumab, for the treatment of rheumatoid arthritis, and talacotuzumab, for the treatment of myeloid leukemia, are the drugs that have been discontinued.

$JNJ {{ '2017-10-17T12:09:28+0000' | timeago}} • Infographic

$JNJ Johnson & Johnson Earnings AlphaGraphic: Q3 2017 Highlights

$HOLX {{ '2017-10-17T12:00:00+0000' | timeago}} • Announcement

Medical technology company $HOLX said the European Medical Device Directive has granted an additional certification for its body contouring laser treatment SculpSure. The certification allows the company to use the device in the European Union and its member states.

$UNH {{ '2017-10-17T11:55:37+0000' | timeago}} • Infographic

$UNH UnitedHealth Earnings AlphaGraphics: Q3 2017 Highlights

$JNJ {{ '2017-10-17T11:47:16+0000' | timeago}} • Announcement

$JNJ raised its sales and adjusted earnings guidance for FY17. The New Brunswick, NJ-based healthcare giant now expects sales for the period to be in the range of $76.1 - 76.5Bil, verses the prior guidance of $75.8 - 76.1Bil. Adjusted earnings is anticipated to be $7.25 - $7.30 per share, compared to the prior guidance of $7.12 - $7.22 per share.

$JNJ {{ '2017-10-17T11:36:50+0000' | timeago}} • Announcement

Kicking off the earnings season in healthcare sector, $JNJ reported 10.3% growth in its sales to $19.7Bil in 3Q17. Adjusted earnings also rose double digits to $5.2Bil, or $1.90 per share, driven by strong growth in Pharma unit, as well as Actelion acquisition. On a GAAP basis, earnings fell 12% to $3.8Bil, or $1.37 per share.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$JNJ {{ '2017-10-16T14:43:30+0000' | timeago}} • Announcement

$JNJ said Janssen Biotech Inc. has received FDA approval for an expanded indication for STELARA for the treatment of adolescents with plaque psoriasis.

$AGN {{ '2017-10-12T22:44:22+0000' | timeago}} • Announcement

$AGN, which inked a controversial patent deal with Mohawk Tribe, reached a patent litigation settlement on its dry eye treatment drug Restasis with InnoPharma, a unit of $PFE. The litigation, which was filed in Sept. 2015 by Allergan, will be withdrawn and Allergan will grant license to InnoPharma to market Restasis from Feb. 2024 or earlier.

$AGN {{ '2017-10-10T18:02:39+0000' | timeago}} • Announcement

FDA accepts to review $AGN's New Drug Application seeking approval for ulipristal acetate, an investigational drug for the treatment of abnormal bleeding in women with uterine fibroids. Allergan expects the action date to occur in 1H18. According to the Agency for Healthcare Research and Quality (AHRQ), 26MM women in U.S. have got uterine fibroids.

$VIVO {{ '2017-10-10T16:19:48+0000' | timeago}} • Announcement

$VIVO has appointed John P. Kenny as CEO, effective October 9, 2017. He has also been appointed to $VIVO’s BoD effective October 9, 2017. Mr. Kenny comes to $VIVO from Siemens Healthcare. Concurrent with the hiring of Mr. Kenny, John A. Kraeutler, CEO & Chairman of the Board, steps down as CEO and takes the title of Executive Chairman.

$HOLX {{ '2017-10-05T20:22:56+0000' | timeago}} • Announcement

$HOLX received 510(k) clearance from FDA for its Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system. The company said new Panther Fusion module expands system's molecular testing capabilities, increases efficiency and flexibility for the laboratory.

$JNJ {{ '2017-10-05T13:58:49+0000' | timeago}} • Announcement

Animas Corp., a $JNJ Diabetes Care Companies, plans to discontinue the manufacturing and sale of Animas Vibe and OneTouch Ping insulin pumps, close operations and exit the insulin pump business. Animas has selected $MDT as its partner-of-choice to facilitate a seamless transition for patients, caregivers and healthcare providers.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, October 17 2017 - 12:45pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
NEOG (Neogen Corp.)
Tuesday, September 19 2017 - 3:00pm
IMMU (Immunomedics Inc.)
Wednesday, August 16 2017 - 9:00pm
TBPH (Theravance Biopharma, Inc.)
Tuesday, August 8 2017 - 9:00pm
CLDX (Celldex Therapeutics, Inc.)
Tuesday, August 8 2017 - 8:30pm
MYGN (Myriad Genetics, Inc.)
Tuesday, August 8 2017 - 8:30pm
QTNT (Quotient Limited)
Tuesday, August 8 2017 - 12:30pm
BIO.B (Bio-Rad Laboratories, Inc.)
Thursday, August 3 2017 - 9:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, August 3 2017 - 12:00pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
HOLX (Hologic Inc.)
Wednesday, August 2 2017 - 8:30pm
ILMN (Illumina Inc.)
Tuesday, August 1 2017 - 8:30pm
GNMK (GenMark Diagnostics, Inc.)
Tuesday, August 1 2017 - 12:30pm
IDXX (IDEXX Laboratories, Inc.)
Tuesday, August 1 2017 - 12:30pm
OXFD (Oxford Immunotec Global PLC)
Tuesday, August 1 2017 - 12:00pm
QGEN (Qiagen NV)
Friday, July 28 2017 - 1:00pm
QDEL (Quidel Corp.)
Wednesday, July 26 2017 - 9:00pm
DHR (Danaher Corp.)
Thursday, July 20 2017 - 12:00pm

AlphaGraphics you may like